LEI:
549300Q7EXQQH6KF7Z84
7 March 2025
RTW Biotech Opportunities
Ltd
(the "Company")
Transaction in Own
Shares
The Company announces that on 6
March 2025 it bought back 100,000 of its Ordinary Shares at a price
$1.305 per Ordinary Share.
The repurchased Ordinary Shares will
be held by the Company in treasury. Following the purchase and
settlement of these Ordinary Shares, the Company's issued Ordinary
Share capital is 345,967,440 of which 10,353,791 Ordinary Shares
will be held in treasury, which attract no voting rights.
Therefore, the total voting rights in the Company will be
335,613,649.
The Company has bought back these
Ordinary Shares under the authority granted by shareholders at its
Annual General Meeting in May 2024, which permits the Company to
repurchase a maximum of 14.99% of its Ordinary Shares. The actual
number of Ordinary Shares repurchased by the Company will depend on
market conditions. This authority lasts until the next shareholder
authority granted (expected to be at the Annual General Meeting in
2025), or until expressly revoked by shareholders.
The above figure of 335,613,649 may
be used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under
the FCA's Disclosure and Transparency Rules.
No maximum consideration payable has
been determined by the Company, but the Company is unable to pay a
price for any Ordinary Shares pursuant to the buyback which would
equate to a premium to the net asset value. It is the Company's
current intention to hold any Ordinary Shares bought back in
treasury.
The Company has instructed Deutsche
Numis as its broker in respect of its buyback transactions. This
arrangement is in accordance with the FCA Listing Rules and the
Company's general authority to repurchase shares.
Enquiries:
|
RTW
Investments, LP - Investment Manager
Woody Stileman (Business
Development)
Oliver Kenyon (Business &
Corporate Development)
Krisha McCune (Investor
Relations)
|
+44 (0)20 7959 6361
biotechopportunities@rtwfunds.com
|
|
Deutsche Numis - Joint Corporate Broker
Freddie Barnfield
Nathan Brown
Euan Brown
|
+44 (0)20 7260 1000
|
About
RTW Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE:
RTW) is an investment fund focused on identifying transformative
assets with high growth potential across the biopharmaceutical and
medical technology sectors. Driven by a long-term approach to
support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and
technologies that can significantly improve patients' lives. RTW
Biotech Opportunities Ltd is managed by RTW Investments, LP, a
leading healthcare-focused
entrepreneurial investment firm with
deep scientific expertise and a strong track record of supporting
companies developing life-changing therapies.
Visit the website
at www.rtwfunds.com/rtw-biotech-opportunities-ltd for
more information.
